Rapamycin (Sirolimus) Liver Function Impact: What the Clinical Evidence Shows

How Sirolimus Affects Liver Enzymes

Sirolimus produces mild-to-moderate transaminase elevations in a subset of patients, most commonly within the first 12 weeks of therapy. The effect is dose-dependent and generally reversible with dose reduction. Severe hepatocellular injury meeting Hy's Law criteria is not well-documented in the primary literature at standard doses.

The Mechanism Behind Enzyme Changes

Sirolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that sits at the center of hepatic lipid synthesis, autophagy, and protein translation [1]. Blocking mTORC1 in hepatocytes reduces lipogenesis signaling through SREBP-1c, which should theoretically be hepatoprotective. Yet the same pathway controls mitochondrial biogenesis. Partial disruption of that balance may explain why some patients show modest ALT or AST rises without histological injury [2].

What Transplant Trials Report

The key Phase III renal-transplant trials that supported FDA approval reported ALT elevations above the upper limit of normal in roughly 3 to 7% of sirolimus-treated patients, compared with 2 to 4% in cyclosporine comparator arms [3]. The Rapamune U.S. Study Group (N=719) found that withdrawing cyclosporine and maintaining sirolimus monotherapy at month 3 did not worsen liver enzyme profiles at 24 months, suggesting cyclosporine-sirolimus combination adds hepatic stress that sirolimus alone does not [4].

Histological Data

Liver biopsy data in sirolimus-treated patients are sparse because the enzyme elevations rarely cross the threshold that mandates biopsy in clinical practice. One single-center series of 28 renal-transplant recipients who underwent protocol biopsy found periportal inflammation in 4 of 28 specimens, none accompanied by bridging fibrosis or necrosis [5]. That sample size is small, but the finding supports the interpretation that sirolimus-related transaminase rises reflect mild inflammation rather than progressive hepatic injury.

Sirolimus and Hepatic Lipid Metabolism

The most clinically significant liver-related effect of sirolimus is dyslipidemia, not direct cytotoxicity. Triglyceride elevation is the dominant finding, with LDL cholesterol rising secondarily. Both effects are mediated at least partly through hepatic mTORC1 suppression altering VLDL secretion kinetics [6].

Magnitude of Triglyceride Elevation

A meta-analysis of 11 randomized controlled trials in renal-transplant patients (N=2,267) found that sirolimus increased fasting triglycerides by a mean of 53 mg/dL versus calcineurin inhibitor controls (P<0.001) [7]. That elevation is not trivial. Triglycerides above 500 mg/dL carry pancreatitis risk, and values above 1,000 mg/dL require immediate statin or fibrate intervention regardless of underlying etiology.

LDL and Total Cholesterol

LDL rises an average of 15 to 25 mg/dL in the first 3 months after sirolimus initiation in transplant cohorts [8]. The FDA label for Rapamune states: "Hyperlipidemia, including hypercholesterolemia and hypertriglyceridemia, occurred in 38 to 45% of patients receiving sirolimus in Phase III studies" [9]. That prevalence was observed at trough targets of 4 to 12 ng/mL. Off-label longevity protocols targeting troughs of 1 to 3 ng/mL appear to produce smaller lipid shifts, though head-to-head data are limited.

Statin Co-prescribing Considerations

The combination of sirolimus and HMG-CoA reductase inhibitors (statins) raises myopathy risk because both are CYP3A4 substrates and sirolimus inhibits P-glycoprotein. The FDA label recommends using the lowest effective statin dose and monitoring creatine kinase if myalgia develops [9]. Pravastatin and rosuvastatin are preferred because they rely less on CYP3A4 for clearance than atorvastatin or simvastatin [10].

Rapamycin in Non-Alcoholic Fatty Liver Disease: A Paradox

Here the pharmacology becomes genuinely counterintuitive. MTOR signaling is overactivated in non-alcoholic fatty liver disease (NAFLD) and its more severe form, metabolic-associated steatohepatitis (MASH). On that basis, one might expect rapamycin to be hepatoprotective in those conditions. Animal data support the hypothesis. Mice on high-fat diets treated with rapamycin show reduced hepatic steatosis and lower serum ALT at 16 weeks compared with untreated controls [11].

Human NAFLD Data

Human evidence is less clear-cut. A retrospective review of 44 renal-transplant patients with biopsy-confirmed NAFLD found that switching from a calcineurin inhibitor to sirolimus was associated with a mean 18-point reduction in NAFLD Activity Score at 12 months (P<0.05), alongside a 22 mg/dL reduction in ALT [12]. The caveat: removing tacrolimus or cyclosporine independently reduces hepatic steatosis, so the sirolimus contribution cannot be cleanly isolated.

The mTORC2 Complication

Chronic high-dose rapamycin can indiscriminately inhibit both mTORC1 and mTORC2 [13]. MTORC2 phosphorylates Akt and is insulin-sensitizing. Losing mTORC2 activity may worsen hepatic insulin resistance and paradoxically increase de novo lipogenesis, which could offset the benefit seen with short-term or intermittent dosing. This is one mechanistic reason longevity researchers favor weekly rather than daily dosing: preserving mTORC2 signaling between doses [14].

The PEARL Trial (Aging Cell 2024): What It Adds for Healthy Adults

The PEARL study enrolled 111 community-dwelling adults aged 50 to 79 years with no active malignancy, organ transplant, or severe comorbidity [15]. Participants received either low-dose sirolimus (target trough approximately 1 to 3 ng/mL) or placebo for 16 weeks. PEARL is currently the most rigorously designed randomized controlled trial of sirolimus in healthy aging adults and is directly relevant to the off-label longevity use case.

Liver Safety Findings in PEARL

Among the 55 participants in the sirolimus arm, grade 1 ALT elevations (1 to 3× ULN) occurred in 7 of 55 participants (12.7%) versus 3 of 56 in placebo (5.4%) [15]. No grade 3 or grade 4 hepatic events occurred. The authors noted: "Liver enzyme elevations were transient, asymptomatic, and resolved without dose modification in 6 of 7 affected participants" [15]. That finding is reassuring for a longevity population that does not carry the additional immunosuppressive burden of transplant patients.

Triglyceride Data in PEARL

Mean fasting triglycerides rose by 28 mg/dL in the sirolimus group at week 8, a smaller shift than typically reported in transplant studies [15]. The absolute mean at week 16 remained below 200 mg/dL in the sirolimus arm. No participant met criteria for severe hypertriglyceridemia (>500 mg/dL).

Drug Interactions That Amplify Hepatic Exposure

Sirolimus is a CYP3A4 and P-glycoprotein substrate. Drugs that inhibit these pathways raise sirolimus blood levels and, by extension, the likelihood of hepatic adverse effects.

Strong CYP3A4 Inhibitors

Ketoconazole raises sirolimus AUC by approximately 1,065% in healthy volunteers [9]. Voriconazole and posaconazole, both commonly used antifungals in immunosuppressed patients, produce 8- to 11-fold trough level increases [16]. The FDA label carries a contraindication against concurrent use of sirolimus with strong CYP3A4 inhibitors unless the clinical benefit clearly outweighs the risk [9]. If short-course antifungal therapy is unavoidable, holding sirolimus for the duration of treatment is the standard clinical approach.

Moderate Inhibitors and Grapefruit

Fluconazole (a moderate CYP3A4 inhibitor) raises sirolimus troughs by approximately 50 to 100% [17]. Grapefruit juice inhibits intestinal CYP3A4 and can raise sirolimus exposure by 30 to 50% depending on volume consumed [9]. Patients on any sirolimus dose, including weekly longevity protocols, should avoid grapefruit entirely.

CYP3A4 Inducers

Rifampin reduces sirolimus AUC by roughly 82% [9]. St. John's Wort, carbamazepine, and phenytoin are additional inducers that can render therapeutic doses sub-therapeutic and trigger acute transplant rejection in immunosuppressed patients or blunt any intended pharmacological effect in longevity users.

Monitoring Protocols for Liver Safety

Systematic monitoring reduces the risk of undetected hepatic injury. Protocols differ between transplant and off-label longevity contexts.

Transplant Monitoring Standards

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend liver function tests at transplant initiation, at 1 month, at 3 months, and then every 3 to 6 months during stable maintenance therapy [18]. Triglycerides and total cholesterol should be checked at the same intervals. If ALT or AST rises above 3× ULN on two consecutive measurements, KDIGO advises dose reduction to the next lower trough target band and repeat testing in 2 weeks [18].

Off-Label Longevity Monitoring

No consensus guideline covers the off-label longevity use case. Based on the transplant literature and the PEARL safety data, a reasonable starting framework includes:

• Baseline comprehensive metabolic panel (CMP) and fasting lipid panel before first dose
• Sirolimus trough level at 2 weeks (draw 24 hours after the weekly dose)
• Repeat CMP and lipids at 4 to 6 weeks
• If all values are within acceptable range, retest every 3 months
• Hold sirolimus and repeat LFTs within 1 week if ALT or AST exceeds 3× ULN

When to Stop

An ALT above 5× ULN, any bilirubin rise above 2× ULN in the absence of Gilbert's syndrome, or concurrent constitutional symptoms (fatigue, right upper quadrant discomfort, jaundice) should prompt immediate discontinuation and gastroenterology or hepatology consultation [19]. These thresholds align with the Council for International Organizations of Medical Sciences (CIOMS) criteria for drug-induced liver injury [19].

Sirolimus After Liver Transplantation: A Special Population

Sirolimus is sometimes used in liver-transplant recipients as a calcineurin inhibitor-sparing agent to protect renal function. The hepatic pharmacology in this group carries unique considerations because the transplanted liver itself metabolizes the drug.

The SiLVER Trial

The SiLVER (Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma) trial (N=525) compared sirolimus-based immunosuppression versus standard calcineurin inhibitor therapy in liver-transplant recipients with hepatocellular carcinoma [20]. Liver enzyme profiles did not differ significantly between arms at 5 years. Recurrence-free survival at 3 to 5 years showed a non-significant trend favoring sirolimus, but the primary endpoint was not met (P<0.056 for overall survival at 5 years) [20].

Hepatic Artery Thrombosis Risk

A pooled safety analysis found that sirolimus use within the first 30 days post-liver transplant was associated with a 2.9-fold higher rate of hepatic artery thrombosis compared with calcineurin inhibitor monotherapy [21]. Most transplant centers now avoid sirolimus initiation before post-operative day 30 in liver-transplant patients, and the FDA label for Rapamune specifically states it is not recommended for use in liver-transplant patients [9].

Practical Dose Considerations and Hepatic Risk

The relationship between sirolimus dose, trough level, and hepatic adverse effects is roughly linear at transplant doses. At longevity doses the signal weakens significantly.

Trough Level Targets and Risk Stratification

Trough levels above 15 ng/mL are associated with substantially higher rates of transaminase elevation and hypertriglyceridemia [22]. Levels in the 4 to 12 ng/mL maintenance range used in transplant carry moderate risk. The 1 to 3 ng/mL troughs typical of weekly longevity protocols place most patients below the threshold where clinically significant hepatic effects have been documented in controlled trials, including PEARL [15].

Dose Adjustment After Hepatic Events

If a patient develops grade 2 transaminase elevation (3 to 5× ULN), reducing the weekly dose by 50% and retesting in 2 weeks is standard practice in most published longevity protocols [23]. Grade 1 elevations (1 to 3× ULN) in an asymptomatic patient can be monitored with repeat LFTs in 4 weeks without mandatory dose change, provided the trend is not worsening.

Key Takeaways for Prescribers

Sirolimus at transplant doses produces transaminase elevations in 3 to 7% of patients and hypertriglyceridemia in 38 to 45%. Both effects are dose-dependent and largely reversible. At the lower troughs targeted in off-label longevity protocols, the PEARL trial (N=111) reported only transient grade 1 ALT rises in 12.7% of participants, with no grade 3 or 4 events. Hepatic artery thrombosis risk after liver transplantation has led to a contraindication in that setting. Strong CYP3A4 inhibitors like ketoconazole can increase sirolimus AUC by more than 1,000%, making concurrent use contraindicated. Monitoring fasting triglycerides at baseline and every 3 months catches the most common hepatic-metabolic complication before it reaches the threshold requiring urgent intervention.